SEC EDGARAUG 201 min read$ARWR

PERRY MICHAEL S sold $1.0M of ARWR

PERRY MICHAEL S sold 11,600 shares of ARROWHEAD PHARMACEUTICALS, INC. (ARWR) at $87.30 ($1.01M total) on 2026-08-18.

Original reporting

SEC EDGAR · PERRY MICHAEL S

Published Aug 20, 2026, 9:22 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Aug 20, 2026, 9:27 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

alphai market briefInsider activity

Primary signal

$ARWR

Bearish

medium confidence

Mentioned

$ARWR

Relevance

6/10

alphai data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$ARWRBearishLow

Why it matters

The Form 4 filing provides the first public disclosure of this insider transaction.

Market read

Insider sales by directors can influence investor sentiment, especially in biotech where insider confidence is closely watched.

What to watch

No accompanying news on drug trials or earnings to contextualize the sale.

Relevance 6/10Novelty 4/10Timing: filed 2026-08-20

Background

Arrowhead Pharmaceuticals is a clinical-stage biotech developing RNAi therapeutics.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ARWRBearishMedium confidence

Context

Director Perry Michael S sold 11,600 shares of Arrowhead Pharmaceuticals for $1.0M, reducing his holdings to 111,459 shares.

Expected impact

Possible modest downward pressure in the near term.

Evidence & confidence

A $1M sale by a director is material for a mid-cap biotech, but the amount is modest relative to market cap.

Market effects

Sector

May raise concerns for biotech sector investors monitoring insider activity.

Regional

Limited to U.S. biotech investors.

Global

Low

Counterpoint

What could challenge this read

The sale could be a routine portfolio rebalancing, not a negative signal.

Key entities

Company
Arrowhead Pharmaceuticals, Inc.
Issuer of the insider transaction.
Person
Perry Michael S
Director and insider who sold shares.

Read at source ← All news

SEP 4

$ARWRHighAI 9/10

Arrowhead (ARWR) Reported a 78% Lower Pancreatitis Event Rate With Plozasiran. Does the Absolute Benefit Support a Broader Label?

Arrowhead Pharmaceuticals (ARWR) reported Phase 3 trial results for plozasiran, showing 79-81% triglyceride reductions vs. 27% for placebo. Pooled analysis indicated a 78% reduction in pancreatitis events, but absolute risk reduction was 4.1%. ARWR plans to submit a broader-label application by 2026. Plozasiran is FDA-approved for familial chylomicronemia syndrome. The company aims to expand its use to severe hypertriglyceridemia. Triglyceride reductions were consistent, with 91-93% of treated p

insidermonkey.com2 min

AUG 31

$ARWRMedAI 8/10

Plozasiran durably cuts triglycerides, pancreatitis risk in severe hypertriglyceridemia

Plozasiran, an FDA-approved drug by Arrowhead, reduced triglycerides by up to 81% in severe hypertriglyceridemia patients and prevented pancreatitis. Two trials, SHASTA-3 and SHASTA-4, showed sustained reductions and favorable safety profiles. Gerald F. Watts, a cardiometabolic medicine professor, highlighted the therapy's potential impact on clinical practice. The drug is not yet approved for severe hypertriglyceridemia.

healio.com2 min

AUG 31

$ARWRHighAI 8/10

Arrowhead’s new Redemplo findings in severe hypertriglyceridemia have analysts split

Arrowhead Pharmaceuticals presented late-stage trial results for plozasiran (Redemplo) in severe hypertriglyceridemia, showing favorable safety and efficacy. Analysts are divided: Stifel highlights its safety and dosing advantages over Ionis' Tryngolza, while BMO favors Tryngolza due to glycemic control concerns. Arrowhead plans an FDA submission for expanded use later this year.

biospace.com3 min

AUG 30

$ARWRHighAI 8/10

Arrowhead Pharmaceuticals, Inc.: Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglycer

Arrowhead Pharmaceuticals presented Phase 3 data showing plozasiran reduced triglycerides by 79-81% and acute pancreatitis events by 78% in severe hypertriglyceridemia patients. Over 90% of patients achieved TG levels below 500 mg/dL. The company plans to file an FDA application by year-end 2026, utilizing a Priority Review Voucher. Plozasiran demonstrated a favorable safety profile.

finanznachrichten.de2 min

AUG 17

$ARWRMedAI 8/10

People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides

Arrowhead Pharmaceuticals (NASDAQ: ARWR) said the European Commission approved REDEMPLO (plozasiran) in June 2026, and it is now listed in Germany’s Lauer-Taxe database for prescribing and reimbursement. REDEMPLO is used with diet for adult FCS patients, with dosing as a subcutaneous injection every three months. Phase 3 PALISADE showed significant fasting triglyceride reductions at Month 10 versus placebo; common adverse reactions included hyperglycaemia and headache.

ir.arrowheadpharma.com4 min

AUG 11

$ARWRMed

How Investors Are Reacting To Arrowhead Pharmaceuticals (ARWR) Soaring Sales But Deepening Losses

Arrowhead Pharmaceuticals (ARWR) reported Q3 2026 results. Sales rose to $75.25 million from $27.77 million a year earlier, but net loss widened to $194.28 million and loss per share increased to $1.36 from $1.26. For the first nine months of 2026, it swung to a $296.21 million net loss despite $400+ million in sales, citing higher expenses and lower collaboration revenue.

simplywall.st6 min